title: Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients.
abstract: Colestimide is a potent therapeutic compound used widely for treatment of hypercholesterolaemia, and it was discovered coincidentally that it can be used to lower the serum phosphate concentration in cases of secondary hyperparathyroidism with refractory hyperphosphataemia. Colestimide is useful for treating hyperphosphataemia in end-stage renal disease (ESRD) patients undergoing haemodialysis. Twenty-eight patients who were being treated for hyperphosphataemia with 3.5+/-1.1 g/day calcium carbonate were enrolled in the study. Colestimide was added to their prescription for 4 weeks at a mean dosage of 2.3 g/day. The serum phosphate concentration decreased significantly from 6.1+/-1.1 mg/dl before treatment to 5.3+/-1.1 mg/dl at 4 weeks (P<0.0001). The calcium-phosphate product also decreased significantly from 59.6+/-11.3 mg/dl(2) before treatment to 50.5+/-12.0 mg/dl(2) (P<0.0001). The serum total cholesterol significantly (P<0.001) decreased at 1 week and remained constant until the end of treatment. Colestimide is a cationic polymer with chloride as the counterion. Its chemical structure resembles that of sevelamer hydrochloride, which is already being used clinically as a phosphate binder. This suggests that colestimide uses the same mechanism as sevelamer hydrochloride to treat hyperphosphataemia. The present results demonstrate that colestimide can function as a Ca-free, aluminium-free, non-absorbable, phosphate binder in ESRD patients. In addition, colestimide can reduce the serum phosphate concentration in combination with calcium carbonate.
authors.affiliation: Jinaikai Date Clinic, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Date
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigematsu
authors.forename: Yoshiteru
authors.initials: Y
authors.lastname: Kawashita
authors.forename: Nobuyoshi
authors.initials: N
authors.lastname: Satake
authors.forename: Kyoko
authors.initials: K
authors.lastname: Morita
mesh_terms: D000328:Adult; D000837:Anion Exchange Resins / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004811:Epichlorohydrin; D005260:Female; D006801:Humans; D007093:Imidazoles; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood / Q000378:metabolism*; D012117:Resins, Synthetic; D014511:Uremia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000837:Anion Exchange Resins; D007093:Imidazoles; D010710:Phosphates; D012117:Resins, Synthetic; C417427:colestimide; D004811:Epichlorohydrin; D002784:Cholesterol; D002118:Calcium